以跨膜蛋白gp41为作用靶点的抗HIV-1药物研究进展  

Research Progress of Anti HIV-1 Drugs Targeting Transmembrane Protein gp41

作　　者：顾觉奋[1] Gu Jue-fen(School of Life Science and Technology,China Pharmaceutical University,Nanjing 210009)

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《国外医药（抗生素分册）》2018年第6期461-471,共11页World Notes on Antibiotics

摘　　要：当今抗人免疫缺陷病毒(HIV)感染的主要方法是高效抗逆转录病毒治疗法(HAART),它为艾滋病患者提供了最好的希望,因为它阻断了HIV病毒的复制过程,改善患者的生命质量并延长生存。但随着HAART的广泛应用,诸如不良反应和耐药毒株等问题也相继出现,因此人们致力于其他抗HIV药物的研究。以跨膜蛋白gp41为相关靶点的HIV-1融合抑制剂是近年来抗HIV-1药物的研究热点。本文对HIV-1进入抑制剂中HIV融合抑制剂,gp41的结构及融膜机制等进行了介绍,并以gp41为作用靶点的抗HIV-1药物的研究进展作一概述。Nowadays, the main method in anti-human immunodeficiency virus （HIV） infection was highly active antiretroviral therapy（HAART）.Antiretroviral treatment had been offered the best hope for AIDS patients, because it could be blocked the replication process of the HIV virus, improving the quality of life and prolonging the survival of the patient. However, with the widespread use of HARRT, there are one after another appeared such as adverse reactions, drug resistant strains, and so on. So people are trying to develop other anti-HIV drugs. HIV-1 fusion inhibitors by transmembrane protein gp41acts as a target was the research hotspot of anti HIV-1 drug in recent years. The inhibitors of HIV fusion in HIV-1 entry inhibitors, structure and fusion mechanism of gp41 have been introduced, and the research progress of anti-HIV-1 drug targeting gp41 have been summarized.

关 键 词：人免疫缺陷病毒 高效抗逆转录病毒疗法 艾滋病 GP41 融合抑制剂 

分 类 号：R978.7[医药卫生—药品]